BackCERo Therapeutics Holdings - Warrants (13/02/2029) Overview

CERo Therapeutics Holdings - Warrants (13/02/2029) Current Assets

Track CERo Therapeutics Holdings - Warrants (13/02/2029)'s current assets ($1.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$1.55M
63.55% YoYΔ $-2.70M vs prior year quarter

Peer trimmed avg / median

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) Current Assets History

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) vs. peers: Current Assets Comparison

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CERo Therapeutics Holdings - Warrants (13/02/2029) (CEROW) FAQ

As of the most recent data (June 2026), CEROW shows a current assets of $1.5M. That compares with $4.2M in the prior-year period — down 63.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CEROW's current assets is now $1.5M (was $4.2M) — a 63.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether CERo Therapeutics Holdings - Warrants (13/02/2029) is outperforming or lagging.

Tracking CEROW's current assets over time shows whether CERo Therapeutics Holdings - Warrants (13/02/2029) is scaling, shrinking, or reshaping that part of the business. The current reading is $1.5M That compares with $4.2M in the prior-year period — down 63.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has CERo Therapeutics Holdings - Warrants (13/02/2029)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $1.5M) with ownership activity and broader fundamentals.